FIG. 2.
Ceramide does not alter phosphorylation or composition of PDGFR or IR complexes. (A) Cells were 32P labeled in vivo prior to 50 μM C2-ceramide treatment for the indicated times, lysis, immunoprecipitation as shown, SDS-PAGE, and phosphorimage scan. (B) Cells were treated with 50 μM C2-ceramide for the indicated times followed by lysis, immunoprecipitation as indicated, SDS-PAGE, immunoblotting as indicated, and fluorimage scan.